

# Better than men? Sex and the therapy/enhancement distinction

Rob Sparrow, Centre for Human Bioethics, Monash University

WORKING PAPER ONLY: NOT FOR CITATION OR DISTRIBUTION

A revised version of this paper will appear as:

Sparrow, R. "Better than men? Sex and the therapy/enhancement distinction," *Kennedy Institute of Ethics Journal* 20 (2)

Please cite that version.

## **Abstract**

The normative significance of the distinction between therapy and enhancement has come under sustained philosophical attack in recent discussions of the ethics of shaping future persons by means of preimplantation genetic diagnosis and other advanced genetic technologies. In this paper, I argue that giving up the idea that whether or not a condition is normal should play a crucial role in assessing the ethics of genetic interventions has unrecognized and strongly counter-intuitive implications when it comes to selecting what sort of children should be brought into the world. According to standard philosophical accounts of the factors we should take into account when making such decisions, women are "better than men". Given the biological differences between the sexes, then, if our only concern is the capacities of an embryo rather than its capacities relative to some normatively significant baseline, we have compelling reason to choose only female embryos. In order to avoid this radical and counter-intuitive conclusion, I suggest, we must embrace the idea that both sexes are normal. The strength of the *prima facie* reasons to select or reject embryos depends on their sex, which is to say that it depends on the normal capacities of their sex. The therapy/enhancement distinction therefore plays a crucial role in determining the ethics of interventions into the genetics of future generations.

## **Keywords**

Human enhancement; PGD; ethics; eugenics; sex; sex selection.

# Better than men? Sex and the therapy/enhancement distinction

## Introduction

The normative significance of the distinction between therapy and enhancement has come under sustained philosophical attack in recent discussions of the ethics of shaping future persons by means of preimplantation genetic diagnosis and other advanced genetic technologies. In this paper, I argue that giving up the idea that the answer to the question as to whether or not a condition is normal should play a crucial role in assessing the ethics of genetic interventions has unrecognized and strongly counter-intuitive implications when it comes to selecting what sort of children should be brought into the world. According to standard philosophical accounts of the factors we should take into account when making such decisions, women are “better than men”. Given the biological differences between the sexes, if our only concern is the capacities of an embryo rather than its capacities relative to some normatively significant baseline, we have compelling reason to choose only female embryos. In order to avoid this radical and counter-intuitive conclusion, I suggest, we must embrace the idea that both sexes are normal. The strength of the *prima facie* reasons to select or reject embryos depends on their sex, which is to say that it depends on the normal capacities of their sex. *Contra* much contemporary bioethical thinking, then, the therapy/enhancement distinction plays a crucial role in determining the ethics of interventions into the genetics of future generations.

In Section 1, I briefly recap the reasons why the therapy/enhancement distinction has mostly fallen out of favour as a way of trying to resolve the vexed question of the ethics of shaping future persons. In Section II, I offer two hypothetical scenarios involving selection between embryos after Preimplantation Genetic Diagnosis (PGD), one involving a disease condition and one involving sex selection, and suggest that the difference in our intuitive response to them can only be explained by the belief that both sexes are “normal”. In Section III of the paper, I further strengthen the argument by outlining a “person affecting” case involving a hypothetical gene therapy. Considering this case also highlights the relationship between the idea of normal human capacities and the therapy/enhancement distinction. In Section IV, I consider various alternative arguments for making different choices in the case of sex selection and selection for disease conditions and argue that, in the absence of a normatively significant account of normal human capacities, the only ways to avoid the conclusion that we have strong reasons prefer female children have equally counter-intuitive implications. Finally, in Section V, I briefly discuss the possible grounds for insisting that both sexes are normal and that an individual’s sex is normatively significant when it comes to attempts to reshape their capacities.

## I. The therapy/enhancement distinction

The distinction between medical therapies designed to cure or prevent sickness and ill-health and those intended to make individuals “better than well” (Elliot 2003) offers an obvious and—at first sight, at least—compelling way of distinguishing the moral status of two different projects that might be undertaken in relation to shaping future persons using genetic technologies, such as preimplantation genetic diagnosis (PGD) or (hypothetical) somatic cell gene therapy.<sup>1</sup> There is widespread popular support for therapeutic genetic interventions, such as screening out genes for disease conditions such as cancer, heart disease, and cystic fibrosis. However, hypothetical genetic “enhancements”, such as selection for genes for increased IQ or longevity, are much more controversial. It might appear, then, that whether a proposed intervention is a therapy or an enhancement is a crucial first question to ask before we go on consider the ethics of proceeding

with it.

However, this way of approaching debates about the ethics of interventions into the genetics of future generations has recently fallen into disrepute amongst philosophers writing about the topic. A number of influential authors have challenged the validity of the distinction between therapy and enhancement itself (Bostrum and Roache, 2008; President's Council on Bioethics, 2003, pp. 14-16; Chan and Harris, 2007). A larger number of authors still have denied the ethical significance of the distinction (Stock, 2003, p. 179; Savulescu, 2006; Savulescu, 2001; Silver, 1999, pp. 252, 277; Harris, 2007, pp. 19-36).

The therapy/enhancement distinction itself has come under attack because of the difficulties involved in delineating it. To start with, there are vexing questions about what precisely the "normal", beyond which therapy becomes enhancement, consists in: is it the capacities of the "average" human today; species-typical capacities; or merely the absence of disease? There are well-known difficulties with each of these answers.<sup>2</sup> Moreover, when it comes to choosing which children to bring into the world on the basis of knowledge about their genetics, the difference between therapy and enhancement seems to be merely a matter of perspective (Chan and Harris, 2007; Silver, 1999, 250-253). Selecting "against" genes with unwanted effects is also necessarily selecting "for" genes with desired effects. As a consequence, embryos that have been selected on the basis of the absence of bad genes are effectively "enhanced" in comparison with embryos that have not benefited by virtue of having been subject to a process of genetic selection. Thus, for instance, using PGD to select an embryo without any of the genes known to contribute to an elevated risk of cancer (therapy) will result in the birth of a person with above average life expectancy (enhancement), insofar as cancer is a cause of early death.

The distinction between therapy and enhancement is therefore extremely difficult to describe and defend. The argument that the distinction has no normative significance is even more compelling. Many existing medical interventions provide individuals with capacities that are beyond species typical. Insofar as we believe that it is at least permissible (cosmetic surgery) and arguably obligatory (vaccination, the Pill) to make these technologies available to people, our existing practice does not locate the distinction between permissible and impermissible interventions at the therapy/enhancement boundary (Kitcher, 1996, p. 124; Buchanan et al., 2000, pp. 153-154; Harris, 2007, pp. 8, 14, 19-28). Similarly, when it comes to environmental interventions, which will have the same or larger effects on the phenotypes of individuals as genetic interventions, we think it entirely appropriate for parents to try to enhance their children, for instance, by providing a stimulating environment or investing in education for them (Harris, 2007, pp. 1-7; Agar, 2004, pp. 111-120; Buchanan et al., pp. 156-161; Harris, 1998, pp. 171-174, 203; Savulescu, 2008, pp. 51-68; Savulescu, 2005, p. 37). More fundamentally, given that our motivation in making therapeutic interventions is to secure some good for the individual who will be born, this concern also seems to motivate pursuit of enhancements. If it is a bad thing to have a reduced life expectancy, for instance, it appears that it should also be a good thing to have an increased life expectancy (Harris, 2007, pp. 9, 45-46; Harris, 2001; Harris, 1993; Savulescu, 2006; Savulescu, 2005). Moreover, to the extent that we are inclined to consequentialism, then failure to convey a benefit may itself be morally blameworthy. If this is true, then our obligation to pursue enhancements will have the same force as our obligation to provide therapy; in both cases we should act so as to promote well-being (Harris, 2007, pp. 58, 145).

These considerations have led many, perhaps even most, philosophers writing about the ethics of shaping future persons to give up on the idea that the therapy/enhancement distinction is a reliable guide to the ethics of particular interventions. At most, the distinction between therapy and enhancement may serve as a useful rule of thumb when considering the sorts of intervention is necessary to make available a fair range of opportunities in a given society (Buchanan et al., 2000,

pp. 119-155). If the normal range of opportunities in a society includes opportunities not available to species-typical human beings then the distinction between therapy and enhancement would cease to play even this role.

Despite these influential and apparently compelling grounds for giving up on the therapy/enhancement distinction as a reliable guide to the ethics of genetic interventions, I believe that we can ill afford to abandon it. As I shall demonstrate, the costs of doing so are high indeed.

## II. Choosing Embryos

In order to understand the implications of abandoning the distinction between therapy and enhancement for the ethics of shaping future persons it will be useful to make reference to a number of imaginary—but not too far-fetched—scenarios. The first of these scenarios involves a hypothetical diagnosis of a real condition in an embryo via PGD.

Mayer-Rokitansky-Kuster-Hauser syndrome is a developmental disorder in female children. Girls born with this syndrome are born without a uterus (or with a severely malformed uterus) although their genitalia and other secondary sexual characteristics are outwardly normal. The syndrome is also associated with disorders of the kidney, skeleton, and heart, although these are by no means present in all cases (Morcel et al., 2007). In many cases, ovaries remain present, which means that it is possible for affected individuals to become genetic parents via IVF—as long as they can find a surrogate mother to bear their child (Beski et al., 2000).

MRKH is believed to have a genetic cause, although the gene or genes involved have yet to be identified (Morcel et al., 2007). However, with our rapidly increasing knowledge of human genetics this is unlikely to remain the case for too much longer. It is therefore not too far-fetched to imagine the following hypothetical scenario.

### Scenario 1

A couple have conceived two embryos using In Vitro Fertilisation (IVF) and have used PGD to find out some information about each embryo. Both embryos are female. One of the embryos (Embryo “B”) is diagnosed as having a sequence of genes that is strongly associated with Mayer-Rokitansky-Kuster-Hauser syndrome. Children with this gene sequence are typically born without a uterus (or with a severely malformed uterus), although their genitalia and other secondary sexual characteristics are outwardly normal; because they possess gonads, it is possible for these individuals to become parents but only if they can find another woman to bear the child. The gene sequence also significantly reduces—by some five years—the life expectancy of those who are born with it.<sup>3</sup> The other embryo (Embryo “A”) does not have this sequence of genes.

Do the parents have good reason to choose one embryo over another? Which embryo should they choose?

Wherever I have presented this scenario and the accompanying questions, an overwhelming majority of the audience, in both philosophical and popular contexts, affirms that the parents do indeed have “good reason” to choose Embryo A.<sup>4</sup> A slightly smaller—but nevertheless still overwhelming—majority are willing, when prompted, to agree that the parents are indeed “obligated” to make this choice.

Of those who dissent from the first majority opinion, a significant percentage do so out of the self-avowed conviction that the absence of uterus in a woman is not a disease or disorder. While I have a

good deal of sympathy with the feminist concerns about the social pressures on women to become mothers that often motivate this response, the high degree of public support for funding for IVF and other programs for treating infertility suggests that many people *do* believe that the capacity to bear children is part of normal health in a premenopausal woman. In most medical settings a diagnosis of infertility in a young woman *would* ground a case for the use of medical resources to try to overcome it. Medical information about MRKH advises that many individuals diagnosed with the condition will experience grief and profound psychological distress when they realise that they won't be able to bear children (Morcel et al., 2007). Few parents would believe that they did not have strong reasons to avoid or remove an environmental hazard that would otherwise result in a young girl needing to have a hysterectomy. While the cultural politics of campaigns for funding for infertility treatment programs may have sometimes have sexist elements and while such campaigns may impact negatively on social stereotypes pertaining to women, there is no *necessary* connection between the desire to ensure that women are able to have children *if they wish to* and the idea that women who choose not to do so are any “less” women (Warren, 1988).

In any case, regardless of our intuitions about the relationship between infertility and health, the loss of life expectancy involved in MRKH is non-negligible. In other circumstances, if scientists could prevent a person's life being shortened by five years they would consider it a tremendous achievement. Considerations of life expectancy alone, then, suggest that the parents have good reason to choose Embryo A.

Those who dissent from the claim that the parents would be *obligated* to choose Embryo A and hold that it would be permissible to choose Embryo B, typically do so for one of two reasons. They may hold that despite the shorter life expectancy and reduced reproductive options associated with it, MRKH is not a “serious” condition (perhaps because they also hold that infertility is not a disease condition) and as such the reasons to select against it fall short of establishing an obligation to do so. Alternatively, they may hold that because the person who will develop from Embryo B will still have a “life worth living” this person will not be harmed by a decision to bring them into existence and therefore that it is permissible to make this choice, even if there are good reasons for preferring Embryo A (Feinberg, 1987). This latter thought is, of course, especially prevalent amongst philosophical audiences who have been exposed to Parfit and the “non-identity problem” (Brock, 1995; Parfit, 1984).

I will have (much) more to say about the “non-identity problem” and its implications for choices of this sort below. At this point, however, let me note the role played by intuitions about “normal human capacities” in underpinning the belief that MRKH is not a “serious” condition. The most natural way to understand the claim that this condition is not serious is by comparing the capacities of a person who has the condition with the capacities of a normal person. If a person with a condition would be seriously impaired relative to a normal person, then the condition is “serious”. Any “absolute” conception of a decent minimum of capacities, below which a person may be said to be suffering from a serious condition, risks being open to the accusation of arbitrariness. That is to say, the question will arise as to why this particular set of capacities, of all the capacities that might be possessed by a human being, including those that might be possessed by an “enhanced” human being, should be the ones we are willing to accept as a decent minimum. We require some independent standard with reference to which we can justify our account of what is acceptable and it is difficult to know what else but a conception of normal human capacities could play this role. Thus, if we abandon the idea that a conception of the capacities of a normal human body has a key role to play in determining the ethics of decisions about shaping future persons—as the arguments (and authors) surveyed above suggest we should—it is hard to see how we could justify insisting that this particular condition is not “serious”.<sup>5</sup>

Of course, we should be extremely cautious about settling important ethical questions through this

type of polling and I am not under any illusions that I have done so here. Instead, I offer these accounts as *prima facie* evidence only that many people do have strong intuitions about the choice we should make in this case.

Current philosophical thinking regarding how we should go about making decisions about shaping future lives also strongly supports choosing Embryo A in the scenario above. Two considerations, which are widely held to be crucial in making such decisions, argue in favour of Embryo A. The person who would develop from Embryo A has both a higher expected welfare and a significantly more “open future” (Feinberg, 1980) than the person who would develop from Embryo B.

If we allow that each extra year of human life includes opportunities to accumulate those things that make a human life “go well”—be they pleasurable experiences, satisfied preferences, objective goods, or some other measure—then Embryo A’s greater life expectancy means that the person who will develop from it will have a higher expected welfare. The expectation of five years of extra life also contributes significantly to the person who will develop from Embryo A’s having a substantially more “open” future than the person who will develop from Embryo B. The person Embryo A will become will be able to pursue longer-term projects than the person Embryo B will become; she will also be able to pursue more projects over the course of her life. Of course, any plausible account of what an open future consists in will refer to the size of the available range of *meaningful* or *significant* options and not merely to the number of options available to a person (Dworkin, 1988, pp. 62-81). However, Embryo A also has a clear advantage over Embryo B in this regard. There is a significant life option—choosing to become pregnant—that is available to the person who will develop from Embryo A, which is not available to the person who will develop from Embryo B. Again, the high level of public support for medical treatments to allow women to become pregnant is compelling evidence that many people do believe that this is a valuable option, which contributes to the openness of futures. As the person who will develop from Embryo A will have all the options available to the person who will develop from Embryo B plus this further valuable option, they will have a significantly more open future.

If this is all the information available to the parents then it seems as though they have good reason to choose Embryo A over Embryo B. Indeed, it seems that they would need to provide some justification for choosing Embryo B.

It does not yet follow that it would be *impermissible* for the parents in Scenario 1 to choose Embryo B. Whether we draw this further conclusion will depend on how we understand the relationship between reason and obligation in non person-affecting cases and also (perhaps) on our assessment of the seriousness of the condition suffered by Embryo B. Note, however, that our “folk intuitions” about the ethics of conception suggest that we *do* have some obligations in relation to choices between persons, as does much of the literature about the ethics of shaping future persons (Brock, 1995, pp. 270-271; Harris, 2007, pp. 88-90; Parfit, 1984, pp. 358-371; Glover, 2001). We do not need to believe that we are always obligated to do what we have most reason to do in non-person-affecting cases in order to conclude that, in circumstances where we could easily avoid bringing children with serious disorders into the world and could bring a healthy child into the world instead, we are obligated to bring a healthy child into the world. The real MRKH arguably *is* sufficiently serious a condition to trigger such an obligation.

I have offered a lengthy explanation and defence of the conclusion that we have good reason to prefer the birth of a normal girl rather than a girl with MRKH here because I want to anticipate and avert disputes about this initial intuition that may be prompted by the argument later in the paper. However, let me at this point re-emphasise how uncontroversial a conclusion this is: when facing a choice between bringing a child suffering from a significant genetic disorder into the world or a child without this condition, parents have a strong moral reason to prefer the child without the

condition.

Now let me establish the central problematic around which this paper is structured by setting out *another* hypothetical scenario. This scenario strongly resembles the one above, except for the fact that the name of the syndrome has been altered slightly (as per the italicised characters below), and except for one further subtlety, which will become obvious in a moment. Thus,

### **Scenario 2**

A couple have conceived two embryos using IVF and have used PGD to find out some information about each embryo. One of the embryos (Embryo “B”) is diagnosed as having a sequence of genes that is strongly associated with *Maybe-Rotikansky-Kaster-Hauber* syndrome. Children with this gene sequence are born without a uterus, although their genitalia and other secondary sexual characteristics are outwardly normal; because they possess gonads, it is possible for these individuals to become parents but only if they can find another person to bear the child. The gene sequence also significantly reduces—by some five years—the life expectancy of those who are born with it. The other embryo (Embryo “A”) does not have this sequence of genes.

Do the couple have good reason to choose one embryo over another? Which embryo should they choose?

While audiences are often—rightly—suspicious of what they are committing themselves to in responses to this example, the obvious homologies between Scenario 1 and Scenario 2 do produce the same sorts of responses to this, as to the preceding, scenario. The vast majority of audience members acknowledge that the parents have good reason to choose Embryo A. A smaller, but still large majority, affirm that the parents are *obligated* to choose Embryo A.

The philosophical considerations surveyed above also support at least the first, and arguably the second, of these conclusions. Embryo A has both a higher expected welfare and a significantly more open future than Embryo B. If this is all the information available to the parents then it seems as though they have good reason to choose Embryo A over Embryo B. Indeed, it seems that they would need to provide some justification for choosing Embryo B. Furthermore, as far as any *obligation* to select Embryo A is concerned, it appears that the parents are obligated—or not—precisely to the same degree as they were in the previous scenario.

Of course, *Maybe-Rotikansky-Kaster-Hauber* syndrome is “maleness”.<sup>6</sup> If the parents have good reasons to select Embryo A it seems as though they have good reason to choose a female child. If the parents are obligated to select Embryo A then they are obligated to have a girl child. It seems that we have reasons to avoid the birth of male children that are precisely as strong as our reasons to avoid the birth of female children suffering from a serious medical disorder.

If we are inclined to recoil at this point it is, I think, because we have a strong intuition that maleness *is not a deficit* and is instead part of normal human variation. Scenario 2 involves a choice between two normal embryos, a normal male embryo and a normal female embryo; consequently, we have no reason to prefer one or the other. In Scenario 1, on the other hand, we are faced with a choice between a normal embryo and an embryo with a serious genetic disorder and have reason to prefer the normal embryo. Thus, our intuitions about what is normal, and about our reasons—or rather, lack of reasons—to alter what is normal, are playing a crucial role here. However, the idea that the normal capacities of human beings should be normatively significant in this way is precisely what is under threat in contemporary bioethics.

### III. The “Person Affecting” Case

Thus far, I have been discussing examples which involve choosing between embryos. It might be argued that we have no obligations arising out of the interests of the future child, as long as they will have a life worth living, because the “non-identity problem” means that children cannot be harmed by a decision that brings them into existence (Brock, 1995; Parfit, 1984, Chapter 16; Glover, 2006, p. 50; Savulescu, 2002). As we will do no harm whichever choice we make, it is permissible to choose either embryo.

However, it is possible to illustrate the perverse consequences of a making choices about future human beings in the absence of an account of normal human capacities in a context that it is “person affecting” and consequently does not raise the non-identity problem. Imagine...

#### Scenario 3

A couple are told that they have produced only one viable embryo and that this embryo has been diagnosed with the gene sequence associated with “MRKH”. Fortunately—they are informed by the attending clinicians—a safe and low-cost intervention involving recombinant DNA technology has recently been developed, which can entirely mitigate the effects of this condition. If they choose to employ it, this procedure will significantly extend the life of their child and also ensure that their child will be capable of bearing children.

What should the parents do?

If “MRKH” is Mayer-Rokitansky-Kuster-Hauser syndrome, then the parents are arguably *obligated* to provide the treatment for their embryo, as a failure to do so will leave their child with a significantly lowered expected welfare and a less open future (Harris, 1993, pp. 182-184). We would certainly judge parents harshly who fail to treat a disease condition in their daughter, acquired after birth, that would result in an expected loss of five years of her life and would require her womb to be removed.

What if “MRKH” is *Maybe-Rotikansky-Kaster-Hauber* syndrome? As described, the impact of the condition on the life prospects of the future child is precisely the same. Unless we are willing to hold that whether a set of capacities is normal is relevant to the reasons we have to alter them, I do not see how we can avoid the conclusion that the parents are still obligated to proceed with the treatment; that is to say, they are obligated to ensure that their child is born with the capacities of a normal woman.<sup>7</sup> In this scenario there can be no recourse to the non-identity problem to avoid this provocative conclusion.<sup>8</sup>

Of course, for the moment, any conclusions that we reach about this person-affecting case are, for the most part, of theoretical interest only because the technology involved is hypothetical. Nevertheless, the conclusion that we are obligated to treat male embryos for their reproductive and longevity deficits is of significant theoretical interest in so far as I think that most readers will find this an unpalatable conclusion. Once more, ideas about the normal capacities of sexed human bodies play a crucial role in determining our intuitions about the example. If the “genetic condition” in Scenario 3 is Mayer-Rokitansky-Kuster-Hauser syndrome then the procedure is a treatment for a disorder and we are obligated to provide it. If this genetic condition is maleness, on the other hand, then the “treatment” is clearly an enhancement; moreover, most people will deny that the parents are obligated to provide it in this case. The strength of our reasons to proceed with the intervention depend on the sex of the embryo, which is to say they depend on the normal capacities of its sex.

In this person-affecting case it is easy to see the relationship between the idea of normal human



capacities and the therapy/enhancement distinction. However, our intuitions about the relative strengths of the reasons to pursue therapy or enhancement also play a role in determining our responses to scenarios 1 and 2, although the non-person-affecting nature of the choices involved obscures it in those cases. Our strong intuition that the parents should select against (the real) MRKH in Scenario 1 is determined by the logic of therapy. In Scenario 2, the argument that we have good reason to prefer female embryos over male embryos participates in the logic of enhancement and consequently we find it much less compelling. Again, an account of the normal capacities of each sex underpins a distinction between therapy and enhancement.

Before leaving this example, it is worth noting that, in the context of debates about resource allocation in healthcare and medical research, the implication that we would be obligated to provide the capacities of female children to male children if it became possible to do so *does* have some practical import because it suggests that we are under some obligation to *develop* the technology. In the absence of the distinction between therapy and enhancement, it would appear that we should respond to men's lack of wombs in the same way as we respond to the causes of infertility in women (Sparrow, 2008). Similarly, we should respond to men's lower life expectancy as compared to women with the same urgency as we would to a circumstance which shortened the lives of women by five years. There is a strong case, then, for investing significant amounts of resources into medical research directed to addressing these disadvantages. Depending on what we think about people's right to healthcare, we may even be obligated to do so.

However, even if we are obligated to pursue it, a technology to transform the reproductive capacities of men in this way is obviously a long way off, whereas the technology involved in the two embryo case—PGD—is readily available now. For the remainder of the paper I will therefore concentrate on the non-person-affecting case.

## IV. Problematic Explanations

In this section I address a number of possible objections to the idea that we have compelling reasons to select girl children and argue that, in the absence of the notion of a normal human body, the only ways to avoid the conclusion that we have such reasons have equally counter-intuitive implications—that we have good reason to prefer male children, or alternatively, no reason to avoid the birth of children with the genetic predisposition to MRKH described in Scenario 1.

### **There are other sex-related biological differences**

The scenarios above involve choices described “all other things being equal”. However, it might be objected that we have good reasons to believe that all other things are *not* equal in the case of choosing between a male and a female embryo and that other differences between the sexes should be included in the description of Scenario 2. Men are not just short-lived women without wombs and there are arguably reasons to believe that Embryo B in Scenario 2 will have genes for capacities that Embryo B in Scenario 1 lacks. These capacities might be enough to explain why our intuitions differ in scenarios 1 and 2 above and to prevent it being the case that parents have reason to select girl children.

The history of claims about differences in the capacities of the sexes is not a happy one. All too often in the past biomedical science has “discovered” that women are unable—or unsuited—to do what men would prefer they didn't. We would be well advised, therefore, to be cautious about claims that there are some things—other than a narrow range activities around reproduction and the sex act—that men can do that women cannot. Of course, it is possible, perhaps even likely, that there are further biological differences between the sexes beyond the difference in reproductive

capacities and life expectancy I have specified in Scenario 2. What is much less obvious though, is that these differences mean that there is a significant range of meaningful life options that are available to men as a result of their biology, which are not available to women as a result of theirs.

The “advantage” associated with being male that is most often mentioned in this context is “higher physical strength”. Those born male may well be better able to realise life plans involving lifting heavy objects—and perhaps also other athletic achievements—than women. Yet such life plans are not unavailable to women unless described with reference to particular—and suspiciously arbitrary—goals (dead lifting 455 kg) rather than the goods internal to the practice of attempting to realise these sorts of goals (striving, grunting, and heaving). Moreover, it is hard to believe that having a better chance of success in pursuing such essentially aesthetic projects could plausibly outweigh the benefits of five years of extra expected life plus the capacity to bear a child, which women have. If physical strength is the only sex difference other than those already acknowledged in my scenarios then, on any plausible account of the relative merits of different option sets, the opportunities available to women will be superior.

A more promising—but also much more controversial—argument for the existence of a distinctive set of life options for men might be made on the basis of a claim about “brain sex” (Hoag, 2008). If men and women have subtly different cognitive capacities and psychological dispositions, these might establish that they have different prospects of success when pursuing various life options. However, again, these differences—if they exist—seem likely to consist in matters of degree rather than in the existence of options that are unique to men. Again, it is debatable whether they are worth as much as a longer life expectancy and the opportunity to give birth. Finally, the empirical premise required here—“brain sex”—is extremely controversial and its introduction in this context seems more than a little post-hoc. There are few, if any, other contexts in which serious intellectuals would argue that innate sex differences meant that men were capable of succeeding in meaningful projects that women were not.

Let me concede though, for argument’s sake, that there might be valuable options available to men that are not available to women, which compensate for or outweigh the greater extent of women’s lives and the valuable choice (pregnancy and birth) that is open to them and not available to men. Even if this is true, it is highly unlikely to establish that there is no reason to prefer male or female embryos. Once we start down the path of evaluating the relative merits of different capacities and sets of options it is extremely improbable that we will find that those available to men and women are of precisely equal worth. Our strong intuition that the capacities of men and women are “equally good” is in reality a conviction that they are both “good enough” and itself relies on the idea that both sexes are normal.

It is, indeed, implausible to think that things as complex as “futures”, consisting in paired sets of options and chances of succeeding in each, can always be compared to one other and ranked according to how “open” they are. While such comparisons may be possible in many cases, it seems that in other cases neither of two sets of options may be said to be larger than the other—instead they may simply be different and incommensurable. In such cases, we may be inclined to conclude that neither of the two option sets is better or worse than the other. It is this thought that explains the intuition that women do not have more open futures than men. Colloquially, we might express this by saying that the options available to men and women are “equally good”.

However, importantly it is *not* plausible to hold that *all* sets of options are “equally good”, as this would void arguments from the openness of futures altogether. Instead, option sets must meet some ill-defined threshold before they are “good enough” to be judged “equally good”. As I suggested above, it seems that we must set this threshold with reference to a conception of normal human capacities.

There is a further, more profound, difficulty with insisting that the capacities of men are equally good as those of women because they are “good enough”, which is that it then seems probable that we must revise our intuitions in Scenario 1. Why should it be the case that only sex difference establishes incommensurable differences in life options that prevent there being reason to choose one embryo or another? Other genetic variations will also subtly alter the life options available to individuals. For instance, young women growing up with MRKH are likely to have a distinctive set of experiences, around their diagnosis and subsequent responses to it, which in turn may subtly shape them so as to render them better able to realise some life plans and less able to realise others. If the options available to men are good enough for us to refrain from comparing them to those of women then surely so too should be the options available to women with MRKH?

It is tempting, here, to respond that the futures available to men include options unavailable to women whereas those available to individuals with MRKH do not. This (empirical) claim might itself be contested on the grounds that MRKH should not be understood as producing only deficits in relation to normal female capacities (perhaps the fact that pregnancy is not an option for women with MRKH means that they are better able make use of other female traits to pursue some projects than are normal women). Moreover, there are relevant cases, such as deafness or Asperger’s syndrome, where it is plausible to hold that genomic variations *do* generate valuable life options that are not available to normal women, as the existence of the condition typically correlates with the development of capacities *not* possessed by species-typical individuals (Rettenbach, Diller, and Sireteanu, 1999; Baron-Cohen, 2000). However, the real problem with this rejoinder is that it renders the case for incommensurability contingent on a comparison with normal human capacities. That is, it measures the capacities of individuals against the capacities of a normal woman and then, after assessing that these individuals have access to valuable options that women do not, declares their option sets to be incommensurable in comparison with those of normal women and therefore equally as good as those of women. It is far from clear that we can individuate capacities without comparing the options they make available, as is required here in order for it to be possible that option sets could be incommensurable while capacities are commensurable. Consequently, it is hard to avoid the impression that the claim about incommensurability is being made on an *ad hoc* basis to make room for the selection of male embryos. Regardless, without an account of the capacities of a normal woman it will not be possible to distinguish between cases where futures should be said to be incommensurable with those of a normal woman and cases where they should not. This way of trying to rescue the equality of the options available to the sexes therefore surreptitiously makes use of the distinction between therapy and enhancement.

Postulating further biological differences between women and men may invalidate the analogy between scenarios 1 and 2 as I have presented them here. It will also complexify the process of determining which of men or women have higher expected welfare or a more open future at birth. It may even lead to the conclusion that parents should choose male children in preference to female children. However, without drawing on an account of normal human (female) capacities, it will *not* establish that there is no reason to prefer children of one sex or the other when it comes to the question of what sort of people we should bring into the world.

### **Sexism means that it is better to be male**

If we cannot explain why we have no reason to prefer one or another of the sexes on the basis of the biological capacities of men and women, perhaps social factors are relevant here? The existence of pervasive and profound institutional sexism in all societies around the world means that male children are likely to have a significantly more open future and higher expected welfare than female children once we take these social factors into account.

It is important to observe of this strategy that, as with the preceding line of objection, if it works, it

works too much. Given the prevalence and impact of sexism, it would seem that parents “have good reason to” or perhaps “are obligated to”, choose male children, if they should take social factors into account when making decisions about what sort of children to bring into the world. It seems highly unlikely that the social advantages of being a man should exactly equal the biological disadvantages. Thus, this strategy will not succeed in denying that parents have reasons to choose one sex or the other—although it may alter our conclusion about which sex they should choose.

However, the idea that injustice can give us good reason to bring certain sorts of people into the world is extremely controversial, as can be brought out by considering...

#### **Scenario 4**

A couple have conceived two embryos using IVF and have used PGD to find out some information about each embryo. Embryo B is diagnosed as having a sequence of genes associated with being born with dark skin. Embryo A is diagnosed as having a sequence of genes associated with being born with white skin. In the racist society in which the couple live, children born with white skin have 110% of the life expectancy of children born with dark skin. The couple want to implant one embryo into the woman’s womb in order to have a child

Do the parents have good reason to choose one embryo or the other? Which embryo should they choose?

I have presented this scenario to the same audiences to which I have presented the scenarios above. In this case, though, their responses are dramatically different. The vast majority of the audience typically now deny that the parents have good reason to select one embryo over the other. A larger—indeed now overwhelmingly large—majority denies that the parents are obligated to choose Embryo A. Most people are reluctant to allow that the existence of bigotry and discrimination can give us reason to prefer children who will benefit from these injustices.

Of course, the same caveat, noted above, about the philosophical significance of such “folk intuitions” also applies here. Yet philosophers are typically equally reluctant to acknowledge that the existence of oppressive social circumstances can establish moral reasons for parents to select children of a particular sort. There are at least two reasons for this reluctance.

Firstly, as per the ordinary “folk”, many philosophers are also worried that allowing that unjust social institutions can give parents morally compelling reasons to choose certain sorts of children would be to concede too much to bigotry and those who promulgate it. Contemporary debates around PGD and gene therapy are taking place in the shadow of the evils done by the Nazis in the name of a concern to improve human beings. Participants in these debates are understandably nervous about endorsing the pursuit of ideals of perfection based on nothing more than the prejudices of the times (Wikler, 1999).

Moreover, when it comes to the welfare of future persons, the argumentative gap between acknowledging the existence of morally compelling reasons and the justification of law is small. In so far as the welfare of children is a proper concern of the community, the community has some grounds to legislate to encourage—or even require—parents to act on the basis of the reasons that bear upon them in relation to the welfare of their children. The fact that decisions about what sorts of people to bring into the world will not harm or violate the rights of those selected is some comfort here. It might be argued that non-person-affecting reasons are never sufficient to justify restrictions on individual liberty (Savulescu, 2002; Harris, 2007, pp. 72-85, 94-95). Yet it is far from obvious why that should be the case; morally compelling reasons related to the welfare of others look like the sort of reasons that might justify the use of state power.<sup>9</sup> Moreover, while the birth of

children who will have reduced welfare as result of social conditions will not involve harm to these children themselves, it *will* impose costs on other members of the community, in so far as they are required to support taxation to improve the welfare of the worst off and because social inequality impacts on the welfare of all members of the unequal societies. The fact that parents' failure to act in accordance with the moral reasons they have would impose such costs on other members of the community may well justify legislation to ensure that parents act as they should (Sparrow, 2007). Thus, the second reason why (some) philosophers are reluctant to endorse the conclusion that parents have good reason to select children favoured by the prevailing social conditions is the recognition that doing so may have further (repugnant) eugenic implications.

The idea that we should neglect “merely” social determinants of the life prospects of individuals when making decisions about which people to bring into the world does call into question one of the lines of reasoning set out above as to why we should choose female children.

The fact that life expectancies of both men and women have changed enormously over the last 150 years as a result of changes in public health, lifestyle, and medical care is convincing evidence that at least some of the differences in the life expectancy of men and women are the result of social factors. It is arguable that some of the reduction in the life expectancy of men is attributable to factors that are themselves a product of (sexist) social relationships between the sexes. For instance, if men receive preferential treatment when it comes to access to high social status jobs and there are significant negative health impacts associated with these jobs, then this will tend to reduce the life expectancy of men (Cameron and Bernardes, 1998). Similarly, where it exists, the male violence that enforces patriarchy also exacts a toll on men (Stanistreet, Bamba, and Scott-Samuel, 2005). The intuition explored here, that we should discount reasons arising from injustice, would suggest that we should not allow considerations of male life expectancy in these circumstances to determine our choice about sex selection.

However, while some of the difference in life expectancy between men and women is undoubtedly the result of injustice, it also seems likely that some of this difference is the result of biological differences between the sexes that will lead to women having an increased life expectancy across a range of environments (Institute of Medicine Committee on Understanding the Biology of Sex and Gender Differences, 2001). Thus, it seems that the argument that women have a high expected welfare and the more open future by virtue of having a longer life expectancy retains some—albeit difficult to quantify—force. If it turns out that the difference in life expectancy between male and female embryos is solely a result of social factors then any argument for selecting female over male embryos will rely upon the more open future available to women due to their superior reproductive capacities.

How to factor considerations relating to the impact of social institutions and environments on the life prospects of future individuals into our decision making about what sort of people to bring into the world is, I believe, the hardest question surrounding the ethics of such decisions. In so far as we should be guided by a concern for the well-being of those we bring into the world and given that the social environment into which children are born will have a large impact on their well-being then it seems we should take social factors into account. Yet concerns about the eugenic implications of doing so seem equally pressing. I cannot hope to resolve this issue here. For the purposes of the current argument, the observation that if we do think parents should take unjust social relations into account when deciding what sort of people to bring into the world then we must conclude that they have compelling reason to choose only male children, serves to show that recourse to the social impact of sexism can at best replace one problematic conclusion with another—equally problematic—one.

## **Aggregate impacts?**

Another set of objections to the idea that we have good reasons to choose female children refer to the aggregate impacts of people acting on the basis of the considerations discussed above. If everyone selected girl children then the circumstances in which these children would grow up would be very different to the world today. A world consisting only of women might be a world with reduced levels of important goods associated with sexual diversity. A large reduction in the number of men might also impact on the life prospects of individual women, in particular by rendering it impossible for heterosexual women to find a mate. Finally, we might worry about the reproduction of the species in such a world. It might therefore be argued that one or more of these aggregate effects establish counter-vailing reasons sufficient to deny that parents have reason to select one sex or the other in making decisions about sex selection.

I am inclined to agree that these aggregate impacts are significant and go a good way towards explaining what would be wrong with pursuing a policy of selecting only female children. However, I also believe that the willingness to rethink the reasons bearing on parents on these grounds surreptitiously draws on the idea that maleness is normal.

There are three reasons to doubt that these concerns will succeed in establishing that the dilemma I have highlighted here does not exist without making reference to the distinction between therapy and enhancement.

Firstly, the force of such arguments from aggregate effects depends on the costs to individuals of acting so as to avoid bringing them about. Requiring individuals to take on burdens for the sake of some social or collective good, such as diversity or the prospects of the species, is precisely the sort of “eugenic” argument that bioethicists have been at pains to avoid endorsing elsewhere in debates about genetic interventions.<sup>10</sup> The existence of women with Mayer-Rokitansky-Kuster-Hauser syndrome undoubtedly contributes to “diversity” (and arguably contributes to other substantial goods, such as the availability of opportunities for learning, sympathy, and compassion), yet we would be reluctant to conclude that parents should not select against MRKH for the sake of maintaining these social goods. If we remain fully conscious of the reduction in life expectancy and openness of future associated with being born male rather than female, then we should be equally reluctant to conclude that parents should not select against maleness. It is the intuition that—because maleness is a normal part of human variation—we do not impose a burden on those born male (or their parents) in pursuing a policy that results in male children being born that explains why we are willing to countenance arguments from aggregate effects as relevant to the reasons bearing on parents in this case.

Secondly, to the extent to which we do believe that we should take into account the aggregate effects of obligations bearing on parents, we must negotiate a collective action problem. While it is true that bringing about the hypothesised aggregate effects will impact negatively on future persons, it is not true that (individual) parents’ choices will bring about these effects. Thus even if we think that parents have good reason to prefer to avoid an aggregate effect, it doesn’t follow that they shouldn’t make the choice which—if universalised—would bring the effect about. While policy makers may have good reason to prohibit sex selection on the basis of its aggregate effects, couples will still have good reason to choose children of the sex which allows them the highest expected welfare and most open future.<sup>11</sup> Again, it is one thing to discount these reasons when the “suboptimal” choice involves the choice of a normal child; it is arguably quite another if we are unwilling to acknowledge any distinction between therapy and enhancement.

Finally, these sorts of objections are vulnerable to the response that there are alternative ways of avoiding the negative consequences associated with the aggregate impact, which do not require some individuals to be born with lower welfare and fewer life options than others. The survival of the species in an all-female world could be ensured by developing stem cell technologies to produce sperm from somatic cells, thereby allowing women to “father” as well as bear children (Aldhous,

2008). The negative implications of altered sex ratios for the ability of heterosexual women to find partners could be avoided by selecting for—or engineering, or otherwise shaping—girl children to be same-sex attracted. If sexual diversity *per se* is a good then we might try to produce a number of distinct variations (preference for redheads, preference for forceful women, preference for shorter women, etc) in the sexual preferences of same-sex attracted women. If these suggestions seem *outré*, it is worth remembering that the literature around human enhancement, which has challenged the therapy/enhancement distinction, regularly considers more outlandish and less feasible interventions into human nature than these.<sup>12</sup>

The aggregate effects of acknowledging that we have good reasons to select female children are indeed confronting. However, both our sense of the losses involved in bringing about a world without men and our willingness to discount the reasons parents have for preferring female children on the basis of aggregate impacts ultimately rest on the conviction that maleness is normal and that selection against maleness is not therapy.

## V. Defending Dimorphism

My survey of these various objections has shown that it is possible to resist the conclusion that if we abandon the therapy/enhancement distinction we have good reason to select female children, but only at the price of concluding that we have good reason to select male children or that we have no reason to select against MRKH in Scenario 1. The conclusion that we have good reason to select male children is no less counterintuitive than the conclusion that we have good reason to select female children. Moreover, the most plausible argument to this conclusion, which proceeds via the impact of sexism, has further morally repugnant implications. The conclusion that we have no reason to select against MRKH is superficially attractive if we think of it as involving the acceptance of diversity, but comes at an unfeasibly high cost to our intuitions about our reasons to select against disease conditions that will lower the welfare and restrict the opportunity of those born with them. Thus, it seems we are confronted with the horns of a dilemma. Either we admit that we have strong reason to bring only children of one sex (most plausibly, female children) into the world or we admit that both sexes are normal and acknowledge a distinction between therapy and enhancement.

My aim in this paper has been to demonstrate the force and currency of this dilemma. No doubt some philosophers will be willing to seize the less familiar horn and embrace the conclusion that we have strong reasons to prefer one sex or the other. Perhaps the most challenging implication of my analysis here is that it reveals just how profound is the tension between the maximising rationality characteristic of most contemporary—especially utilitarian—bioethics and the fact of sexual difference. The logic of trying to improve human beings without limit points towards a single sex species.

I believe that we should instead defend dimorphism. In order to avoid the paradoxical and unappealing conclusions I have outlined here, we need to reconsider the current trend to abandon the therapy/enhancement distinction. That is, we should reaffirm the folk intuitions I surveyed at the outset of this paper and insist on a distinction between selecting against (the real) MRKH and selecting against maleness. MRKH is a disease condition, while maleness is not, and our reasons to prevent disease are significantly stronger than our reasons to enhance normal capacities. The relevant standard against which to measure proposed interventions is a conception of normal human capacities that is bifurcated and consists in the capacities of a normal man *and* the capacities of a normal woman. Our intuitions about the medical treatment appropriate to different people are therefore deeply infused with ideas about (biological) sex.<sup>13</sup> As a consequence, some interventions that would be enhancement of one sex are therapies in the other. This way of thinking about the

ethics of shaping future persons, then, allows that the distinction between therapy and enhancement properly plays a crucial role in thinking about this issue.

There is not enough space remaining to me here to defend or motivate this choice at length; for the purposes of the current paper its plausibility must rest, to a large degree, on the unattractiveness of the alternatives. However, I believe that this choice may also be defended by referring to certain natural facts about the human species and to the way in which these facts establish a background context against which human actions have their meaning. *Homo sapiens* is a dimorphic species, which reproduces sexually, and these facts in turn condition and give sense to many of our experiences and our projects, including what are for many people their most intimate and engaging projects. Abandoning dimorphism would therefore involve a tremendous transformation of the human life-world. This is not to deny that a different set of experiences and projects would become available and would take on significance in a world in which human beings were no longer divided into men and women. Further, there may be no independent, “God’s eye” perspective that would allow the evaluation of the relative merits of these two very different worlds. Thus, it might well be true that, if we were to become fully accustomed to a single-sex world, we would not regret the loss of dimorphism. Yet, in so far as *we* do not identify with and value those choices that might become available in a world without sex and we *do* identify with and value our existing choice set, we have reason to defend dimorphism (Glover, 2006, p. 97).

Obviously, more would need to be said to establish that the desire to defend the meanings of those human choices that are conditioned by the fact of dimorphism justifies abandoning the pursuit of enhancements, especially in so far as this is likely to require restricting the liberty of those individuals who would like to pursue enhancements, or programmes of research, which, in the long term, would contribute to the erosion of sexual dimorphism. This is a larger task than I can attempt in this paper.<sup>14</sup> However, I have sketched the general direction of the argument here in order to show that there are, plausibly, independent grounds upon which to motivate the defence of dimorphism.

Establishing that the cost of giving up the therapy/enhancement distinction are too high, as I have argued here, does not in itself do anything to meet the challenges involved in setting out that distinction that I surveyed at the outset of my discussion. Delineating the distinction between therapy and enhancement will require a plausible account of normal human capacities that is appropriately sensitive to the range of natural variation amongst human beings, the impact of these variations on welfare, the biology of the species, and the extent to which our intuitions about the normal are shaped by technology and culture. Beyond insisting that our ideas about the normal should allow for sexual dimorphism, I have said nothing here to offer such an account. This urgent philosophical task also remains to be addressed in further research. Until we have such an account we cannot explain why we do not have good reason to use sex selection technologies to make the next generation “better than men” by making sure that they are female.<sup>15</sup>

## References

- Agar, Nicholas. 2004. *Liberal Eugenics: In Defence of Human Enhancement*. Oxford: Blackwell.
- Aldous, P. 2008. Male Eggs and Female Sperm. *New Scientist* 197(2641):6-7.
- Australian Bureau of Statistics. 2008. *Australian Historical Population Statistics*. 3105.0.65.001.
- Baron-Cohen, S. 2000. Is Asperger Syndrome/High Functioning Autism Necessarily a Disability? *Development and Psychopathology* 12:489-500.



- Beski, Shohre, Gorgy, Amin, Venkat, Gheeta, Craft, Ian L., and Edmonds, Keith. 2000. Gestational Surrogacy: A feasible option for patients with Rokitansky syndrome. *Human Reproduction* 15(11):2326-2328.
- Bostrum, Nick, and Roache, Rebecca. 2008. Ethical Issues in Human Enhancement. In *New Waves in Applied Ethics*, ed. T. S. Petersen, J. Ryberg and C. Wolf, pp. 120-152. Hampshire: Palgrave Macmillan.
- Brock, Dan. 1995. The Non-Identity Problem and Genetic Harms. *Bioethics* 9(3/4):269-275.
- Buchanan, Allen, Brock, Dan W., Daniels, Norman, and Wikler, Daniel . 2000. *From Chance to Choice*. Cambridge: Cambridge University Press.
- Cameron, Elaine, and Bernardes, Jon. 1998. Gender and disadvantage in health: men's health for a change. *Sociology of Health & Illness* 20(5):673-693.
- Chan, Sarah, and Harris, John. 2007. In Support of Human Enhancement *Studies in Ethics, Law, and Technology* 1.1.
- Cooper, Rachel. 2002. Disease. *Studies in the History and Philosophy of Biology & the Biomedical Sciences* 33:263-82.
- Dworkin, Gerald. 1988. *The Theory and Practice of Autonomy*. Cambridge: Cambridge University Press.
- Elliott, Carl. 2003. *Better than well: American medicine meets the American dream*. New York: W.W. Norton.
- Fausto-Sterling, Anne. 2000. *Sexing the Body: Gender Politics and the Construction of Sexuality*. New York: Basic Books.
- Feinberg, Joel. 1987. Wrongful Life and the Counterfactual Element in Harming. *Social Philosophy & Policy* 4(1):145-178.
- Feinberg, Joel. 1980. The Child's Right to an Open Future. In *Whose Child? Children's Rights, Parental Authority, and State Power*, edited by W. Aiken and H. LaFollette. Totowa, N.J.: Littlefield, Adams & Co.
- Glover, Jonathan. 2006. *Choosing Children: Genes, Disability, and Design*. Oxford: Oxford University Press.
- Glover, Jonathon. 2001. Future People, Disability, and Screening. In *Bioethics*, edited by J. Harris. Oxford: Oxford University Press.
- Habermas, Jurgen. 2003. *The Future of Human Nature*. Cambridge, England: Polity Press.
- Harris, John. 2007. *Enhancing Evolution: The Ethical Case for Making Better People*. Princeton, NJ: Princeton University Press.
- Harris, John. 2001. One Principle and Three Fallacies of Disability Studies. *Journal of Medical Ethics* 27:383-387.
- Harris, John. 1998. *Clones, Genes and Immortality: Ethics and the Genetic Revolution*. Oxford:

Oxford University Press.

Harris, John. 1993. Is Gene Therapy a Form of Eugenics? *Bioethics* 7(2/3):178-187.

Hoag, Hannah. 2008. Sex on the Brain. *New Scientist* 199(2665):28-31.

Institute of Medicine Committee on Understanding the Biology of Sex and Gender Differences. 2001. *Exploring the Biological Contributions to Human Health: Does Sex Matter?*, edited by Theresa M. Witzmann and Mary-Lou Pardue. Washington, D.C.: National Academy Press.

Intersex Society of North America. 2008. *A World Free of Shame, Secrecy, and Unwanted Genital Surgery* (<http://www.isna.org/>, accessed 23.12.2008)

Kessler, Suzanne J. 1998. *Lessons from the Intersexed*. New Brunswick, New Jersey, and London: Rutgers University Press.

Kitcher, Philip. 1996. *The Lives to Come: The Genetic Revolution and Human Possibilities*. New York: Simon and Schuster.

McKibben, Bill. 2003. *Enough: Staying Human in an Engineered Age*. New York: Times Books.

Morcel, Karine, Camborieux, Laure, Programme de Recherches sur les Aplasies Müllériennes, and Guerrier, Daniel. 2007. Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome. *Orphanet Journal of Rare Diseases* 2(13).

Parens, E. 1995. The Goodness of Fragility: On the Prospect of Genetic Technologies Aimed at the Enhancement of Human Capabilities. *Kennedy Institute of Ethics Journal* 5(2):141-153.

Parfit, Derek. 1984. *Reasons and Persons*. Oxford: Clarendon Press.

Persson, Ingmar, and Savulescu, Julian. 2008. The Perils of Cognitive Enhancement and the Urgent Imperative to Enhance the Moral Character of Humanity. *Journal of Applied Philosophy* 25(3):162-177.

President's Council on Bioethics. 2003. *Beyond Therapy: Biotechnology and the Pursuit of Happiness*. New York: Regan Books.

Rettenbach, R., Diller, D., and Sireteanu, R. 1999. Do Deaf People See Better? Texture Segmentation and Visual Search Compensate in Adult but not in Juvenile Subjects. *Journal of Cognitive Neuroscience* 11(5):560-583.

Sandel, Michael J. 2007. *The case against perfection: ethics in the age of genetic engineering*. Cambridge, Mass.; London: Harvard University Press.

Savulescu, Julian. 2008. Procreative Beneficence: Reasons Not to Have Disabled Children. In *The Sorting Society*, edited by L. Skene and J. Thomson. Cambridge, New York: Cambridge University Press.

Savulescu, Julian. 2006. Genetic Interventions and the Ethics of Enhancement of Human Beings. In *The Oxford Handbook on Bioethics*, edited by B. Steinbock. Oxford: Oxford University Press.

Savulescu, Julian. 2005. New Breeds of Humans: The Moral Obligation to Enhance. *Ethics, Law and Moral Philosophy of Reproductive Biomedicine* 1(1):36-39.

- Savulescu, Julian. 2002. Deaf lesbians, “designer disability”, and the future of medicine. *British Medical Journal* 325:771-775.
- Savulescu, Julian. 2001. Procreative Beneficence: Why we should select the best children. *Bioethics* 15(5):413-426.
- Silver, Lee M. 1999. *Remaking Eden: Cloning, Genetic Engineering and the Future of Human Kind*. London: Pheonix.
- Skene, Loane, and Thompson, Janna, eds. 2008. *The Sorting Society: The Ethics of Genetic Screening and Therapy*. Cambridge: Cambridge University Press.
- Sparrow, Robert. 2008. Is it ‘every man’s right to have babies if he wants them’? Male pregnancy and the limits of reproductive liberty. *Kennedy Institute of Ethics Journal* 18(3):275-299.
- Sparrow, Robert. 2007. Procreative Beneficence, Obligation, and Eugenics. *Genomics, Society, and Policy* 3(3):43-59.
- Sparrow, Robert. 2000. History and Collective Responsibility. *Australasian Journal of Philosophy* 78(3):346-359.
- Stanistreet, D., Bambra, C., and Scott-Samuel, A. 2005. Is patriarchy the source of men’s higher mortality? *Journal of Epidemiology and Community Health* 59(10):873-876.
- Stock, Gregory. 2003. *Redesigning humans: choosing our children’s genes*. London Profile Books.
- Warren, Mary Anne. 1988. IVF and Women’s Interests: an Analysis of Feminist Concerns. *Bioethics* 1(2):37-54.
- Wikler, Daniel. 1999. Can we learn from eugenics? *Journal of Medical Ethics* 25(2):183-194.

---

<sup>1</sup> For a recent survey of the issues raised by the “new” genetic technologies, see Skene and Thompson (2008).

<sup>2</sup> The problem of giving an account of “normal” human capacities has been most thoroughly investigated in the literature about the definition of disease. For a useful introduction to this literature, see Cooper, 2002. See also, Bostrum and Roache, 2008; Chan and Harris, 2007; Harris, 2007, pp. 19-32, 44-45, 91-3; Agar, 2004, pp. 78-81; Glover, 2006, pp. 6-14.

<sup>3</sup> Given the range of skeletal and other abnormalities that may occur in MRKH it is plausible to assume a lowered—though not radically so—life expectancy on the basis of a diagnosis of a gene sequence associated with the disorder. Regardless, this aspect of the scenario is stipulated for reasons that will become obvious below.

<sup>4</sup> I have presented versions of this paper to: the 2008 Australasian Association of Philosophy conference; the Centre for Applied Philosophy and Public Ethics at the University of Melbourne; the Centre for Applied Philosophy and Public Ethics at the Australian National University; the James Martin Advanced Research Seminar at the University of Oxford; the Philosophy Programme at Latrobe University; the University of Tokyo Center for Biomedical Ethics and Law; and, the Centre for Social Ethics and Policy at the University of Manchester. My analysis of typical intuitions in response to the various examples in the paper—and the motivations for these responses—in what follows is based on the extensive discussions that took place during and after these seminars.

---

<sup>5</sup> John Harris has argued that we should identify disabling conditions—and I take it that what I here intend by “serious” conditions are a subset of this larger category—by reference to what we would treat if a patient presented to a hospital emergency department. According to Harris, “disabling” conditions are those that it would be negligent not to treat (Harris, 1993, p. 180; Harris, 2007, pp. 92-93). Harris explicitly contrasts his account with a concern for normal human capacities (Harris, 1993, p. 181), arguing that there will be times when it would be negligent not to treat a normal person (Harris, 2001). The obvious difficulty with Harris’s account arises when it comes to providing an account of when we are obligated to intervene (or, when it would be negligent not to treat a condition) that is genuinely independent of intuitions about normal human capacities. A consequence of the argument of my paper is that this difficulty is more profound than Harris acknowledges, as will become clear below. For the moment, it will serve to note that MRKH is clearly a serious condition according to Harris’s criterion: it would be negligent not to treat a woman who presented to an emergency department with an abdominal wound that would result in her not being able to bear children if left untreated.

<sup>6</sup> In Australia, in 2008, life expectancy at birth for males was 78.7 years, for females, 83.5 years (Australian Bureau of Statistics, 2008).

<sup>7</sup> We are now in a better position to be able to understand the difficulty posed for John Harris’s account by the fact of sexual dimorphism. As I noted above, Harris is arguably committed to the claim that MRKH is a disabling condition. What, then, should we say on his account about *Maybe-Rotikansky-Kaster-Hauber* syndrome? Presumably, it would *not* be negligent to fail to treat a man who presented to a hospital emergency department complaining about his lack of a womb. Indeed, Harris (2007, p. 147) explicitly states that gender is a neutral trait and that it is not rational to prefer to be male or female. Yet the only difference between the two different versions of Scenario 3 is whether the capacities are normal or not. Thus, *contra* Harris, it appears that our intuitions about normal human capacities are playing a crucial role in determining what sorts of conditions it would be negligent not to treat.

<sup>8</sup> It might be objected that a genetic modification that changed the sex of an embryo would *not* be person-affecting because such a change would alter who would be born rather than change the properties of the same person. Yet the intervention at issue in this scenario need not involve a chromosomal sex change for male embryos: it might only involve switching back on the genes involved in the development of a womb and also extending their life expectancy. It is, of course, possible to insist that *any* genetic modification is non person-affecting by advancing a genetic theory of personal identity, in which case Scenario 3 collapses into Scenario 1 or Scenario 2, depending on whether “MRKH” is (the real) MRKH or “maleness”. However, the intuition that we have much stronger reasons to proceed with genetic modification in the former case than in the latter remains.

<sup>9</sup> Thus, for instance, states routinely restrict the liberty of individuals to pollute the environment on the grounds that such pollution will harm future generations, even though, as Parfit (1984, pp. 361-364) pointed out, such pollution will also change who will be born and therefore will not result in person-affecting harms.

<sup>10</sup> Of course, describing the burdens and those affected by them is difficult because of the non-person-affecting nature of policy in this area. However, at the very least, parents who are required to have children with reduced well-being are burdened by doing so in so far as their own welfare is linked to that of their children.

<sup>11</sup> Note that this argument may also be used to contest the intuition that we should discount the reasons parents have for selecting children who will benefit as a result of widespread racism, sexism, or homophobia. However, insofar as the (in)justice of a policy is partially determined by its historical resonances and its continuity with existing power relations (see Sparrow, 2000) the selection of males embryos with the intention that they should benefit from sexism may have a different ethical character than the selection of male embryos for the sake of equal sex ratios.

<sup>12</sup> See, for instance, Gregory Stock’s (2003) speculations about the possibility of introducing artificial chromosomes into the human genome in order to allow future individuals to choose whether and when to turn on and off particular genes, Lee Silver’s advocacy of the pursuit of “radiotelepathy” (1999, pp. 278-280), and Persson and Savulescu, 2008.

<sup>13</sup> I am not unaware of the powerful and important “intersex” critique of the idea of sexual dimorphism (Fausto-Sterling, 2000; Intersex Society of North America, 2008; Kessler, 1998); an earlier version of this paper considered it at length in a discussion that I now hope to develop further in another context. In this context, I merely wish to observe that nothing follows (yet) from my argument here in relation to the treatment of children who are born intersex. The question of the appropriate course of action to take when children are born intersex needs to be addressed with proper attention to the ethical dilemmas involved in carrying out elective—and often experimental—surgery on infants for the sake (allegedly)

---

of their psychological well-being, the empirical facts about the success of such surgery, and the details of particular cases—a task that is beyond the scope of this paper.

<sup>14</sup> However, see, Sandel (2007); McKibben (2003); Parens (1995); Habermas (2003).

<sup>15</sup> I would like to thank Hilary Bambrick, Linda Barclay, Victor Cole, Kate Crawford, Toby Handfield, Neil Levy, Terry MacDonald, Larry May, Catherine Mills, and Justin Oakley for comments and discussion which have assisted with the development of this paper. I would also like to thank Emilio Mora for his assistance in preparing the paper for publication.